#GynCSM Transcript
Healthcare social media transcript of the #GynCSM hashtag.
– ().
See #GynCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | OmniComm Systems @OmniCommSystems Complexity is increasing. We’re seeing oncology trials with up to 200 cycles! - Keith. Howells, CTO, #EDC https://t.co/vkpjMephis #gyncsm https://t.co/IpSaGYLPZi |
 | GYN Cancer | #GYNCSM @gyncsm Welcome to #gyncsm - a passionate community of gynecologic cancer survivors, caregivers, advocates and health care providers. |
 | NCI Cancer Stats @NCICancerStats #CervicalCancer is most common among Hispanic and Black women. See more stats: https://t.co/HrwcdqrJQK #GynCSM https://t.co/44JmHqeFEh |
| GYN Cancer | #GYNCSM @gyncsm Our co-moderators are @womenofteal @btrfly12 #gyncsm |
 | Dee Sparacio @womenofteal RT @gyncsm: Welcome to #gyncsm - a passionate community of gynecologic cancer survivors, caregivers, advocates and health care providers. |
| GYN Cancer | #GYNCSM @gyncsm Our health care moderators are @ShannonWestin @DrMarkham @journeycancer and our mental health moderator @DrBeckerSchutte #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm We start out with introductions - Please take a moment to introduce yourself. :) #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Our health care moderators are @ShannonWestin @DrMarkham @journeycancer and our mental health moderator @DrBeckerSchutte #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: We start out with introductions - Please take a moment to introduce yourself. :) #gyncsm |
 | Christina Lizaso @btrfly12 RT @gyncsm: Welcome to #gyncsm - a passionate community of gynecologic cancer survivors, caregivers, advocates and health care providers. |
 | ASCO @ASCO Hi all! American Society of Clinical Oncology (ASCO) here, joining from VA. We rep 40K+ members working to conquer cancer #gyncsm |
| Dee Sparacio @womenofteal Dee here! Dx #ovca Stage3B 2005, OC research advocate, blogger & co-moderator #gyncsm |
| Christina Lizaso @btrfly12 RT @ASCO: Hi all! American Society of Clinical Oncology (ASCO) here, joining from VA. We rep 40K+ members working to conquer cancer #gyncsm |
| Christina Lizaso @btrfly12 Christina Lizaso – passionate re: community engagement and cancer. I’ll be moderating as @gyncsm today. #gyncsm |
| Dee Sparacio @womenofteal RT @ASCO: Hi all! American Society of Clinical Oncology (ASCO) here, joining from VA. We rep 40K+ members working to conquer cancer #gyncsm |
 | Merry-Jennifer Markham, MD, FACP, FASCO @DrMarkham Good evening - MJ Markham here. Medical gyn oncologist at @UFHealthCancer #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm If you prefer to listen only during the chat, we'd love for you to tweet "#gyncsm" when you join just to let us know you are here. #gyncsm |
| Dee Sparacio @womenofteal @ASCO So glad you are here with us tonight! #gyncsm |
| Dee Sparacio @womenofteal @DrMarkham @UFHealthCancer Hi Merry! #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm @ASCO Thanks so much for joining along. Great to have you here. #gyncsm |
| Merry-Jennifer Markham, MD, FACP, FASCO @DrMarkham @ASCO So glad you're joining the conversation! #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: If you prefer to listen only during the chat, we'd love for you to tweet "#gyncsm" when you join just to let us know you are here. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Pls continue intro's and welcomes - we'll start in w/ the "ground rules" :) #gyncsm |
| Merry-Jennifer Markham, MD, FACP, FASCO @DrMarkham @womenofteal Hi Dee! #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm The #gyncsm chat promotes community in a public forum. Learn more about risks/benefits: https://t.co/TipZUv1jQy |
| Dee Sparacio @womenofteal Today's chat is solely informational & not a substitute for speaking w/ a doctor who's familiar w/your medical needs & history. #gyncsm |
 | Rie Lopez, MPH (she/her) @RieOfLetters Hi everyone! Rie here. So glad to be here with you all tonight! #gyncsm |
 | Tobey @BRCAinfo Hi #gyncsm. Excited to learn about #clinicaltrials tonight 👏 |
| Dee Sparacio @womenofteal @RieOfLetters Hi !! So glad you are here. #gyncsm |
| Christina Lizaso @btrfly12 @RieOfLetters welcome - always great to tweet with you :) #gyncsm |
| Dee Sparacio @womenofteal @BRCAinfo great to see you tonight. Hope you are feeling ok. #gyncsm |
 | Emily K. Drake @EK_Drake #gyncsm - I'm doing some course readings but I'll follow along as much as I can! |
| Christina Lizaso @btrfly12 @BRCAinfo yay! so glad you can check in in real time this month :) #gyncsm |
| Dee Sparacio @womenofteal Remember- Twitter is an open social network & posts are public.Use a DM to exchange email addresses/personal info #gyncsm |
| Christina Lizaso @btrfly12 @EK_Drake :) #gyncsm |
 | Jillosopher, BSN, RN @jillosopher hello #gyncsm Jill from CT, dx Jan/17 grade 1, stage 3a endometrioid endometrial ca. Finished tx May17. |
| GYN Cancer | #GYNCSM @gyncsm #gyncsm is not a forum for medical advice. Resources and referrals are provided solely for information and convenience. |
| Dee Sparacio @womenofteal @EK_Drake Hi Emily! #gyncsm |
| Christina Lizaso @btrfly12 @jillosopher Hope you are doing well. Nice to see you, #gyncsm |
| Dee Sparacio @womenofteal #gyncsm community is here 2 support and inform survivors, med workers & loved ones w/ gyn cancer interest |
| Tobey @BRCAinfo @womenofteal Likewise #gyncsm |
| Dee Sparacio @womenofteal @jillosopher Thanks for joining #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm We also welcome all those “listening in”. You can always tweet us or email us with questions/comments after the chat is over. #gyncsm |
| Dee Sparacio @womenofteal @garmischgirl Welcome Linda #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Great group gathering :) #gyncsm |
 | Jen Burzawa @jburzawa Hi all. Glad to join you tonight #gyncsm. |
| Dee Sparacio @womenofteal Thank you to all who have tweeted during the past month with the #gyncsm hashtag and RT'd about this chat |
| Dee Sparacio @womenofteal @jburzawa Hi Jen. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Tonight we will discuss: #ClinicalTrials - How have they changed? #gyncsm |
 | Dr. Lisa Aiello @aiellolisa136 @gyncsm I'm excited to be here! #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Tonight we will discuss: Tonight we will discuss: #ClinicalTrials - How have they changed? #gyncsm |
| Christina Lizaso @btrfly12 RT @gyncsm: Tonight we will discuss: Tonight we will discuss: #ClinicalTrials - How have they changed? #gyncsm |
| Jillosopher, BSN, RN @jillosopher @btrfly12 Hi Christina, doing OK. Hope all's well with you. #gyncsm |
| Dee Sparacio @womenofteal @crazyknit68 @gyncsm Hi Lisa! Welcome #gyncsm |
| Jillosopher, BSN, RN @jillosopher @womenofteal Thanks, Dee. #gyncsm |
 | Erica Bednar @EMBOSU A bit late, I'm Erica, genetic counselor at @MDAndersonNews with a focus on hereditary gyn cancers #gyncsm https://t.co/ge583b9mxb |
| GYN Cancer | #GYNCSM @gyncsm As moderator, I'll introduce new Topics with T1, T2... Pls include corresponding T# at front of answer -hard to remember but helpful #gyncsm |
 | Shannon Westin, MD, MPH, FASCO @ShannonWestin Hello all! GynOnc from @mdandersonnews Happy to be here and discuss #clinicaltrials #gyncsm |
| Dee Sparacio @womenofteal @EMBOSU @MDAndersonNews Great to have you here, Erica #gyncsm |
| Dee Sparacio @womenofteal @ShannonWestin @MDAndersonNews Hi Shannon! #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: As moderator, I'll introduce new Topics with T1, T2... Pls include corresponding T# at front of answer -hard to remember but helpful #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm See this link for a listing of all the #gyncsm topic questions that will be coming up: https://t.co/p9Ngbc9iw7 |
| Dee Sparacio @womenofteal RT @gyncsm: See this link for a listing of all the #gyncsm topic questions that will be coming up: See this link for a listing of all the #gyncsm topic questions that will be coming up: https://t.co/p9Ngbc9iw7 |
| Christina Lizaso @btrfly12 Resource | Understanding Gynecologic Cancer Clinical Trials https://t.co/uRrAWKcu2z via @GYNCancer #gyncsm |
| Dee Sparacio @womenofteal If you want to learn the basics about clinical trials see @GYNCancer ‘s Guide https://t.co/CKNOidyR6I #gyncsm |
| Christina Lizaso @btrfly12 RT @gyncsm: See this link for a listing of all the #gyncsm topic questions that will be coming up: See this link for a listing of all the #gyncsm topic questions that will be coming up: https://t.co/p9Ngbc9iw7 |
| Merry-Jennifer Markham, MD, FACP, FASCO @DrMarkham RT @womenofteal: If you want to learn the basics about clinical trials see @GYNCancer ‘s Guide https://t.co/CKNOidyR6I #gyncsm |
 | Janet Freeman-Daily @JFreemanDaily Janet Freeman-Daily joining a bit late--#lungcancer patient/advocate in a clinical trial for almost five years. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Tonight we are happy to have @ASCO with us to discuss the TAPUR Study #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @gyncsm: Tonight we are happy to have @ASCO with us to discuss the TAPUR Study #gyncsm |
| Merry-Jennifer Markham, MD, FACP, FASCO @DrMarkham RT @gyncsm: Tonight we are happy to have @ASCO with us to discuss the TAPUR Study #gyncsm |
| Dee Sparacio @womenofteal @JFreemanDaily Hi Friend - Thanks for joining us #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @womenofteal: If you want to learn the basics about clinical trials see @GYNCancer ‘s Guide https://t.co/CKNOidyR6I #gyncsm |
| Dr. Lisa Aiello @aiellolisa136 @gyncsm I'm a genetics nurse with a focus on BRCA1& 2. #gyncsm |
| Christina Lizaso @btrfly12 @JFreemanDaily Thanks so much for joining. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin Hi Dee! #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Tonight we are happy to have @ASCO with us to discuss the TAPUR Study #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm When we last discussed clinical trials in 2013/14 we focused on challenges w/ finding trials and dr/patient convos about trials. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: When we last discussed clinical trials in 2013/14 we focused on challenges w/ finding trials and dr/patient convos about trials. #gyncsm |
| Tobey @BRCAinfo RT @btrfly12: Resource | Understanding Gynecologic Cancer Clinical Trials https://t.co/uRrAWKcu2z via @GYNCancer #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Tonight we'll talk about some of the changes. Our first question T1: (Topic 1) is coming up. #gyncsm |
 | Christian Hinrichs @CSHinrichsMD RT @gyncsm: Tonight we will discuss: Tonight we will discuss: #ClinicalTrials - How have they changed? #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Tonight we'll talk about some of the changes. Our first question T1: Tonight we'll talk about some of the changes. Our first question T1: (Topic 1) is coming up. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T1: What role do #clinicaltrials play in cancer treatment advances? What are some of the key trial design changes in the past 5 yrs? #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T1: T1: What role do #clinicaltrials play in cancer treatment advances? What are some of the key trial design changes in the past 5 yrs? #gyncsm |
| ASCO @ASCO T1: #Clinicaltrials are key to helping us better prevent & detect cancer, find new & better treatments, & manage side effects #gyncsm |
 | Vivek Subbiah, MD @VivekSubbiah RT @ASCO: Hi all! American Society of Clinical Oncology (ASCO) here, joining from VA. We rep 40K+ members working to conquer cancer #gyncsm |
 | Suzie Siegel @SuzieSiegel Hi, I'm a sarcoma advocate. 15-year survivor of metastatic vaginal #leiomyosarcoma. #gyncsm |
| Dee Sparacio @womenofteal RT @ASCO: T1: T1: #Clinicaltrials are key to helping us better prevent & detect cancer, find new & better treatments, & manage side effects #gyncsm |
| ASCO @ASCO T1: New trial designs let us study multiple cancers/treatments at the same time & learn which therapy works best for each patient #gyncsm |
| Dee Sparacio @womenofteal @SuzieSiegel Welcome Suzie. Glad you are joining in. #GYNCSM |
| Dee Sparacio @womenofteal RT @ASCO: T1: T1: New trial designs let us study multiple cancers/treatments at the same time & learn which therapy works best for each patient #gyncsm |
| Janet Freeman-Daily @JFreemanDaily T1: Clinical trials are essential to determine whether new cancer treatments are effective and tolerable for human patients. #gyncsm |
| Dee Sparacio @womenofteal RT @JFreemanDaily: T1: T1: Clinical trials are essential to determine whether new cancer treatments are effective and tolerable for human patients. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin T1: #clinicaltrials are how we make advances in cancer treatment, quality of life, and prevention! They are essential! #gyncsm |
| Dee Sparacio @womenofteal RT @ShannonWestin: T1: T1: #clinicaltrials are how we make advances in cancer treatment, quality of life, and prevention! They are essential! #gyncsm |
| ASCO @ASCO T1: Check out our guide for more info on new trial designs & precision medicine: https://t.co/xqqrELXFy3 #gyncsm |
| Dee Sparacio @womenofteal RT @ASCO: T1: Check out our guide for more info on new trial designs & precision medicine: T1: Check out our guide for more info on new trial designs & precision medicine: https://t.co/xqqrELXFy3 #gyncsm |
| Merry-Jennifer Markham, MD, FACP, FASCO @DrMarkham RT @ASCO: T1: Check out our guide for more info on new trial designs & precision medicine: T1: Check out our guide for more info on new trial designs & precision medicine: https://t.co/xqqrELXFy3 #gyncsm |
| Christina Lizaso @btrfly12 T1: I've been hearing about "basket trials", precision medicine and immunotherapy more and more. Making way from lab to trials. #gyncsm |
| Dr. Lisa Aiello @aiellolisa136 Clinical trials are crucial to approving new treatments, and improving side effect profile of treatments. #gyncsm |
| Dee Sparacio @womenofteal RT @btrfly12: T1: T1: I've been hearing about "basket trials", precision medicine and immunotherapy more and more. Making way from lab to trials. #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters RT @ShannonWestin: T1: T1: #clinicaltrials are how we make advances in cancer treatment, quality of life, and prevention! They are essential! #gyncsm |
| Suzie Siegel @SuzieSiegel T1: It's important for patients to understand that #clinicaltrials are NOT the treatment of last resort. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm RT @ASCO: T1: T1: New trial designs let us study multiple cancers/treatments at the same time & learn which therapy works best for each patient #gyncsm |
| Janet Freeman-Daily @JFreemanDaily T1: New trial design: "basket trial" offer single treatment for all cancers with specific biomarker (like ROS1 fusions) #gyncsm |
| OmniComm Systems @OmniCommSystems Wider sources of data such as imaging, instrument output, ePRO, all managed together - Keith Howells, CTO, #gyncsm https://t.co/0ZNl9Q2Se4 https://t.co/CMIpejY6W1 |
| Dee Sparacio @womenofteal More Diversity in Trials is imp. https://t.co/5Eleae6iYe #gyncsm |
| Dee Sparacio @womenofteal RT @JFreemanDaily: T1: New trial design: T1: New trial design: "basket trial" offer single treatment for all cancers with specific biomarker (like ROS1 fusions) #gyncsm |
| Janet Freeman-Daily @JFreemanDaily T1: Another new trial design: "umbrella" trial offers different treatments for single cancer type (liuke squamous cell lung cancer) #gyncsm |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: T1: New trial design: T1: New trial design: "basket trial" offer single treatment for all cancers with specific biomarker (like ROS1 fusions) #gyncsm |
| Christina Lizaso @btrfly12 RT @SuzieSiegel: T1: T1: It's important for patients to understand that #clinicaltrials are NOT the treatment of last resort. #gyncsm |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: T1: Another new trial design: T1: Another new trial design: "umbrella" trial offers different treatments for single cancer type (liuke squamous cell lung cancer) #gyncsm |
| Dee Sparacio @womenofteal RT @JFreemanDaily: T1: Another new trial design: T1: Another new trial design: "umbrella" trial offers different treatments for single cancer type (liuke squamous cell lung cancer) #gyncsm |
| Suzie Siegel @SuzieSiegel T1. There's more understanding that we can't lump all gyn sarcomas together, especially not #carcinosarcoma. #gyncsm |
| Tobey @BRCAinfo THIS. How do we change this? #gyncsm https://t.co/oNoKxZ8V7p |
| ASCO @ASCO @womenofteal Absolutely! This is something we've been focusing on: https://t.co/giQ94TMIO5 #gyncsm |
| Janet Freeman-Daily @JFreemanDaily T1: For patients with specific biomarkers (especially genomic drivers), clinical trial may be best treatment option #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin T1: There are study designs called "basket trials" that include all #cancer types - these trials focus on specific molecular changes #gyncsm |
| Erica Bednar @EMBOSU T1: clinical trials help move us beyond anecdotes & stories to real data to ensure best options to treat and #endcancer #gyncsm https://t.co/gJGk3r7g0E |
| Merry-Jennifer Markham, MD, FACP, FASCO @DrMarkham Important point #gyncsm https://t.co/Rgo2VxufdM |
| Rie Lopez, MPH (she/her) @RieOfLetters @btrfly12 Immunotherapy is definitely trending as a treatment for many types of cancer and it is only in its infancy. Exciting! #gyncsm |
| Dee Sparacio @womenofteal RT @SuzieSiegel: T1. There's more understanding that we can't lump all gyn sarcomas together, especially not #carcinosarcoma. #gyncsm |
 | Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba T1 Clinical Trials are vital 2 the advancement of cancer care initiatives. #PrecisionMedicine & utilization of AI will prove pivotal #gyncsm |
| Christina Lizaso @btrfly12 Another non- randomized Trial is the precision medicine trial know as NCI-MATCH Trial #gyncsm |
 | Cancer Hope Network @CancerHopeNet RT @SuzieSiegel: T1: T1: It's important for patients to understand that #clinicaltrials are NOT the treatment of last resort. #gyncsm |
| Dee Sparacio @womenofteal RT @JFreemanDaily: T1: T1: For patients with specific biomarkers (especially genomic drivers), clinical trial may be best treatment option #gyncsm |
| Dee Sparacio @womenofteal RT @ShannonWestin: T1: T1: There are study designs called "basket trials" that include all #cancer types - these trials focus on specific molecular changes #gyncsm |
| Dee Sparacio @womenofteal RT @EMBOSU: T1: T1: clinical trials help move us beyond anecdotes & stories to real data to ensure best options to treat and #endcancer #gyncsm https://t.co/gJGk3r7g0E |
| GYN Cancer | #GYNCSM @gyncsm Topic 2 (T2:) coming up... https://t.co/p9Ngbc9iw7 #gyncsm |
| Christina Lizaso @btrfly12 RT @ShereesePubHlth: T1 Clinical Trials are vital 2 the advancement of cancer care initiatives. #PrecisionMedicine & utilization of AI will prove pivotal #gyncsm |
 | Kathleen Maxian @KathleenMaxian RT @JFreemanDaily: T1: T1: For patients with specific biomarkers (especially genomic drivers), clinical trial may be best treatment option #gyncsm |
| Dee Sparacio @womenofteal RT @ShereesePubHlth: T1 Clinical Trials are vital 2 the advancement of cancer care initiatives. #PrecisionMedicine & utilization of AI will prove pivotal #gyncsm |
| Suzie Siegel @SuzieSiegel This is crucial for non-endometrioid uterine cancers that occur more often in African-American women. #sarcoma https://t.co/q8iQvve8Lp |
| Dee Sparacio @womenofteal RT @btrfly12: Another non- randomized Trial is the precision medicine trial know as NCI-MATCH Trial #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin T1: "Umbrella" trials have multiple therapies for one type of cancer (ie ovarian) - the arm may be chosen based on molecular testing #gyncsm |
| Suzie Siegel @SuzieSiegel Forgot #gyncsm ... https://t.co/p0JSDMWiOu |
| Tobey @BRCAinfo RT @DrMarkham: Important point #gyncsm https://t.co/Rgo2VxufdM |
| Dee Sparacio @womenofteal More effort designing trials for adolescents https://t.co/vYNp2FTPVE #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm One trial that has changed the landscape is TAPUR which leads up to Topic 2... #gyncsm |
 | Gordon Vansant @gvansant1 RT @JFreemanDaily: T1: T1: For patients with specific biomarkers (especially genomic drivers), clinical trial may be best treatment option #gyncsm |
| Tobey @BRCAinfo RT @RieOfLetters: @btrfly12 Immunotherapy is definitely trending as a treatment for many types of cancer and it is only in its infancy. Exciting! #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: One trial that has changed the landscape is TAPUR which leads up to Topic 2... #gyncsm |
| Tobey @BRCAinfo RT @ShereesePubHlth: T1 Clinical Trials are vital 2 the advancement of cancer care initiatives. #PrecisionMedicine & utilization of AI will prove pivotal #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T2: What is TAPUR? Why did @ASCO develop this trial? Who can participate? What makes TAPUR different from other trials? #gyncsm |
| Dee Sparacio @womenofteal Here is a link to NCI-MATCH info https://t.co/etEw6iBYNp @theNCI #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T2: T2: What is TAPUR? Why did @ASCO develop this trial? Who can participate? What makes TAPUR different from other trials? #gyncsm |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba @womenofteal How are you? #gyncsm |
| Kathleen Maxian @KathleenMaxian RT @gyncsm: T2: T2: What is TAPUR? Why did @ASCO develop this trial? Who can participate? What makes TAPUR different from other trials? #gyncsm |
| Dee Sparacio @womenofteal #gyncsm https://t.co/O9BvAioVz6 |
| Kathleen Maxian @KathleenMaxian RT @womenofteal: Here is a link to NCI-MATCH info https://t.co/etEw6iBYNp @theNCI #gyncsm |
| Christina Lizaso @btrfly12 RT @gyncsm: T2: T2: What is TAPUR? Why did @ASCO develop this trial? Who can participate? What makes TAPUR different from other trials? #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @womenofteal: Here is a link to NCI-MATCH info https://t.co/etEw6iBYNp @theNCI #gyncsm |
| ASCO @ASCO T2: #TAPUR stands for the Targeted Agent and Profiling Utilization Registry Study and is our first clinical trial ever #gyncsm |
| Dee Sparacio @womenofteal RT @ASCO: T2: T2: #TAPUR stands for the Targeted Agent and Profiling Utilization Registry Study and is our first clinical trial ever #gyncsm |
| Suzie Siegel @SuzieSiegel More adult #sarcoma trials are allowing AYAs and children, with proper safety protocols. #gyncsm https://t.co/RMTiHP6ZpR |
| Kathleen Maxian @KathleenMaxian RT @ASCO: T2: T2: #TAPUR stands for the Targeted Agent and Profiling Utilization Registry Study and is our first clinical trial ever #gyncsm |
| ASCO @ASCO T2: The study matches pts w/ targeted therapies based on tumors’ specific genomic profiles https://t.co/0uYnM5PMWJ #gyncsm |
 | Christian Ntizimira @ntizimira RT @ASCO: T2: T2: The study matches pts w/ targeted therapies based on tumors’ specific genomic profiles https://t.co/0uYnM5PMWJ #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters #clinicaltrials are an important consideration even early following diagnosis. Perception can change through education and outreach #gyncsm https://t.co/fbRs5Xy90B |
| Dee Sparacio @womenofteal RT @ASCO: T2: T2: The study matches pts w/ targeted therapies based on tumors’ specific genomic profiles https://t.co/0uYnM5PMWJ #gyncsm |
| ASCO @ASCO T2: Our CMO @rschilsky and Past Pres. @DrJulieVose explain why ASCO developed the TAPUR study in this video: https://t.co/j9qEuIY3tY #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin T1: The MATCH trial run by @theNCI selects specific treatments based on the molecular abnormalities found in a patient's tumor #gyncsm |
| Kathleen Maxian @KathleenMaxian RT @ASCO: T2: T2: The study matches pts w/ targeted therapies based on tumors’ specific genomic profiles https://t.co/0uYnM5PMWJ #gyncsm |
| Merry-Jennifer Markham, MD, FACP, FASCO @DrMarkham RT @ASCO: T2: Our CMO @rschilsky and Past Pres. @DrJulieVose explain why ASCO developed the TAPUR study in this video: T2: Our CMO @rschilsky and Past Pres. @DrJulieVose explain why ASCO developed the TAPUR study in this video: https://t.co/j9qEuIY3tY #gyncsm |
| Dee Sparacio @womenofteal RT @RieOfLetters: #clinicaltrials are an important consideration even early following diagnosis. Perception can change through education and outreach #gyncsm https://t.co/fbRs5Xy90B |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @ASCO: T2: T2: #TAPUR stands for the Targeted Agent and Profiling Utilization Registry Study and is our first clinical trial ever #gyncsm |
| Christina Lizaso @btrfly12 RT @ASCO: T2: T2: #TAPUR stands for the Targeted Agent and Profiling Utilization Registry Study and is our first clinical trial ever #gyncsm |
| Kathleen Maxian @KathleenMaxian RT @ASCO: T2: Our CMO @rschilsky and Past Pres. @DrJulieVose explain why ASCO developed the TAPUR study in this video: T2: Our CMO @rschilsky and Past Pres. @DrJulieVose explain why ASCO developed the TAPUR study in this video: https://t.co/j9qEuIY3tY #gyncsm |
| Dee Sparacio @womenofteal RT @ASCO: T2: Our CMO @rschilsky and Past Pres. @DrJulieVose explain why ASCO developed the TAPUR study in this video: T2: Our CMO @rschilsky and Past Pres. @DrJulieVose explain why ASCO developed the TAPUR study in this video: https://t.co/j9qEuIY3tY #gyncsm |
| Dee Sparacio @womenofteal RT @ShannonWestin: T1: T1: The MATCH trial run by @theNCI selects specific treatments based on the molecular abnormalities found in a patient's tumor #gyncsm |
| Tobey @BRCAinfo RT @RieOfLetters: #clinicaltrials are an important consideration even early following diagnosis. Perception can change through education and outreach #gyncsm https://t.co/fbRs5Xy90B |
| ASCO @ASCO T2: TAPUR is for pts >12yo w/ adv. cancer & at least 1 genomic alteration targetable by a study drug. More: https://t.co/1IQz9miZtg #gyncsm |
| Christina Lizaso @btrfly12 RT @ASCO: T2: Our CMO @rschilsky and Past Pres. @DrJulieVose explain why ASCO developed the TAPUR study in this video: T2: Our CMO @rschilsky and Past Pres. @DrJulieVose explain why ASCO developed the TAPUR study in this video: https://t.co/j9qEuIY3tY #gyncsm |
| Cancer Hope Network @CancerHopeNet RT @ASCO: T2: T2: The study matches pts w/ targeted therapies based on tumors’ specific genomic profiles https://t.co/0uYnM5PMWJ #gyncsm |
| Dee Sparacio @womenofteal RT @ASCO: T2: TAPUR is for pts >12yo w/ adv. cancer & at least 1 genomic alteration targetable by a study drug. More: T2: TAPUR is for pts >12yo w/ adv. cancer & at least 1 genomic alteration targetable by a study drug. More: https://t.co/1IQz9miZtg #gyncsm |
| Vivek Subbiah, MD @VivekSubbiah RT @ASCO: T2: TAPUR is for pts >12yo w/ adv. cancer & at least 1 genomic alteration targetable by a study drug. More: T2: TAPUR is for pts >12yo w/ adv. cancer & at least 1 genomic alteration targetable by a study drug. More: https://t.co/1IQz9miZtg #gyncsm |
| ASCO @ASCO T2: TAPUR is designed to include a broader patient population than most trials & to mirror real-world clinical practice #gyncsm |
 | Ovarian Cancer Proj @WNYOCP RT @womenofteal: Here is a link to NCI-MATCH info https://t.co/etEw6iBYNp @theNCI #gyncsm |
| Christina Lizaso @btrfly12 RT @ShannonWestin: T1: T1: The MATCH trial run by @theNCI selects specific treatments based on the molecular abnormalities found in a patient's tumor #gyncsm |
| Ovarian Cancer Proj @WNYOCP RT @ASCO: T2: T2: #TAPUR stands for the Targeted Agent and Profiling Utilization Registry Study and is our first clinical trial ever #gyncsm |
| Dr. Lisa Aiello @aiellolisa136 @ASCO T2 what do you mean 1st clinical trial ever? #gyncsm |
| Ovarian Cancer Proj @WNYOCP RT @ShereesePubHlth: T1 Clinical Trials are vital 2 the advancement of cancer care initiatives. #PrecisionMedicine & utilization of AI will prove pivotal #gyncsm |
| Ovarian Cancer Proj @WNYOCP RT @ASCO: T2: T2: The study matches pts w/ targeted therapies based on tumors’ specific genomic profiles https://t.co/0uYnM5PMWJ #gyncsm |
| Christina Lizaso @btrfly12 RT @ASCO: T2: T2: TAPUR is designed to include a broader patient population than most trials & to mirror real-world clinical practice #gyncsm |
| Ovarian Cancer Proj @WNYOCP RT @womenofteal: #gyncsm https://t.co/O9BvAioVz6 |
| ASCO @ASCO T2: Check out the study website https://t.co/uK8rRVUicP & FAQs https://t.co/GRJygmH43j for more details! #gyncsm |
| Ovarian Cancer Proj @WNYOCP RT @ASCO: T2: T2: TAPUR is designed to include a broader patient population than most trials & to mirror real-world clinical practice #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters RT @ASCO: T2: T2: The study matches pts w/ targeted therapies based on tumors’ specific genomic profiles https://t.co/0uYnM5PMWJ #gyncsm |
| Dee Sparacio @womenofteal RT @ASCO: T2: T2: TAPUR is designed to include a broader patient population than most trials & to mirror real-world clinical practice #gyncsm |
| Dee Sparacio @womenofteal RT @ASCO: T2: T2: Check out the study website https://t.co/uK8rRVUicP & FAQs https://t.co/GRJygmH43j for more details! #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin @crazyknit68 @ASCO This is the first clinical trial run by @ASCO - it's a paradigm shift! #gyncsm |
| Christina Lizaso @btrfly12 RT @ASCO: T2: T2: Check out the study website https://t.co/uK8rRVUicP & FAQs https://t.co/GRJygmH43j for more details! #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @ASCO: T2: T2: TAPUR is designed to include a broader patient population than most trials & to mirror real-world clinical practice #gyncsm |
| Dee Sparacio @womenofteal RT @ShannonWestin: @crazyknit68 @ASCO This is the first clinical trial run by @ASCO - it's a paradigm shift! #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm RT @ASCO: T2: TAPUR is for pts >12yo w/ adv. cancer & at least 1 genomic alteration targetable by a study drug. More: T2: TAPUR is for pts >12yo w/ adv. cancer & at least 1 genomic alteration targetable by a study drug. More: https://t.co/1IQz9miZtg #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Topic 3 (T3:) coming up... https://t.co/p9Ngbc9iw7 #gyncsm |
| Janet Freeman-Daily @JFreemanDaily T2: TAPUR is an option for patients to access targeted drug that is approved for a different cancer than theirs #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Topic 3 (T3:) coming up... https://t.co/p9Ngbc9iw7 #gyncsm |
| Dee Sparacio @womenofteal RT @JFreemanDaily: T2: T2: TAPUR is an option for patients to access targeted drug that is approved for a different cancer than theirs #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm RT @JFreemanDaily: T2: T2: TAPUR is an option for patients to access targeted drug that is approved for a different cancer than theirs #gyncsm |
| Janet Freeman-Daily @JFreemanDaily T2: For example, patient with ROS1+ cancer that started in colon can get ROS1 targeted drug approved for lung cancer #gyncsm |
| Dee Sparacio @womenofteal RT @JFreemanDaily: T2: T2: For example, patient with ROS1+ cancer that started in colon can get ROS1 targeted drug approved for lung cancer #gyncsm |
| Dr. Lisa Aiello @aiellolisa136 @ShannonWestin @ASCO T2 Thx Did't realize it wasn't coop group. I guess this is needed to allow 4 broader range of tumor types #gyncsm |
| Kathleen Maxian @KathleenMaxian RT @ASCO: T2: T2: Check out the study website https://t.co/uK8rRVUicP & FAQs https://t.co/GRJygmH43j for more details! #gyncsm |
| Christina Lizaso @btrfly12 Several years ago Susan Gubar wrote about the Rainbow Coalition - as the organ of origin starts to matter less in cancer treatment #gyncsm |
| Suzie Siegel @SuzieSiegel This is great for #sarcoma patients. Repurpose those drugs for us! (I got remission from 2 drugs not approved for #sarcoma.) #gyncsm https://t.co/k0E3rE1co3 |
 | Ann Becker-Schutte @DrBeckerSchutte Hi all! I'm Ann, KC psychologist, #gyncsm mental health mod. Late to the party, but excited about tonight's topic. |
| Dee Sparacio @womenofteal T2 more info on TAPUR on @cancerdotnet https://t.co/s6tr25n2Nb #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @btrfly12: Several years ago Susan Gubar wrote about the Rainbow Coalition - as the organ of origin starts to matter less in cancer treatment #gyncsm |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba RT @ASCO: T2: T2: Check out the study website https://t.co/uK8rRVUicP & FAQs https://t.co/GRJygmH43j for more details! #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @OmniCommSystems: Wider sources of data such as imaging, instrument output, ePRO, all managed together - Keith Howells, CTO, #gyncsm https://t.co/0ZNl9Q2Se4 https://t.co/CMIpejY6W1 |
| Christina Lizaso @btrfly12 RT @womenofteal: T2 more info on TAPUR on @cancerdotnet https://t.co/s6tr25n2Nb #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @JFreemanDaily: T1: New trial design: T1: New trial design: "basket trial" offer single treatment for all cancers with specific biomarker (like ROS1 fusions) #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @SuzieSiegel: T1: T1: It's important for patients to understand that #clinicaltrials are NOT the treatment of last resort. #gyncsm |
| Vivek Subbiah, MD @VivekSubbiah RT @SuzieSiegel: This is great for #sarcoma patients. Repurpose those drugs for us! (I got remission from 2 drugs not approved for #sarcoma.) #gyncsm https://t.co/k0E3rE1co3 |
| Ann Becker-Schutte @DrBeckerSchutte RT @crazyknit68: Clinical trials are crucial to approving new treatments, and improving side effect profile of treatments. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @btrfly12: T1: T1: I've been hearing about "basket trials", precision medicine and immunotherapy more and more. Making way from lab to trials. #gyncsm |
 | Enlightening Results 💡 @GraceCordovano @RieOfLetters Yes. Therapies have come a long way. Trials shouldn't be viewed as a last resort, discuss up front w/other treatment options #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @ShannonWestin: T1: T1: #clinicaltrials are how we make advances in cancer treatment, quality of life, and prevention! They are essential! #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T3: What are Patient Reported Outcomes (PRO)? What progress have you seen on ensuring that trials meet patients' needs/interests? #gyncsm |
| Dr. Lisa Aiello @aiellolisa136 T2 This will allow for advances in #precision medicine #gyncsm |
| Vivek Subbiah, MD @VivekSubbiah RT @ASCO: T2: T2: TAPUR is designed to include a broader patient population than most trials & to mirror real-world clinical practice #gyncsm |
| Christina Lizaso @btrfly12 RT @gyncsm: T3: T3: What are Patient Reported Outcomes (PRO)? What progress have you seen on ensuring that trials meet patients' needs/interests? #gyncsm |
| ASCO @ASCO T3: PROs are anything reported directly by the patient, like symptoms or emotions. They reflect how patients feel & function #gyncsm |
| Dee Sparacio @womenofteal @DrBeckerSchutte Hi Ann Glad you are here tonight. #gyncsm |
| Vivek Subbiah, MD @VivekSubbiah RT @ASCO: T2: T2: The study matches pts w/ targeted therapies based on tumors’ specific genomic profiles https://t.co/0uYnM5PMWJ #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin @crazyknit68 @ASCO Yes - @ASCO is an advocacy group for cancer patients and physicians - its awesome they are running a trial #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T3: T3: What are Patient Reported Outcomes (PRO)? What progress have you seen on ensuring that trials meet patients' needs/interests? #gyncsm |
| Dee Sparacio @womenofteal RT @ASCO: T3: T3: PROs are anything reported directly by the patient, like symptoms or emotions. They reflect how patients feel & function #gyncsm |
| Kathleen Maxian @KathleenMaxian RT @gyncsm: T3: T3: What are Patient Reported Outcomes (PRO)? What progress have you seen on ensuring that trials meet patients' needs/interests? #gyncsm |
| Christina Lizaso @btrfly12 RT @ASCO: T3: T3: PROs are anything reported directly by the patient, like symptoms or emotions. They reflect how patients feel & function #gyncsm |
| Kathleen Maxian @KathleenMaxian RT @ASCO: T3: T3: PROs are anything reported directly by the patient, like symptoms or emotions. They reflect how patients feel & function #gyncsm |
| ASCO @ASCO T3: More trials are incorporating PROs so outcomes can be measured against pts’ needs/interests https://t.co/L02FN4tcgW #gyncsm |
| Jen Burzawa @jburzawa RT @ShannonWestin: @crazyknit68 @ASCO Yes - @ASCO is an advocacy group for cancer patients and physicians - its awesome they are running a trial #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters RT @SuzieSiegel: This is great for #sarcoma patients. Repurpose those drugs for us! (I got remission from 2 drugs not approved for #sarcoma.) #gyncsm https://t.co/k0E3rE1co3 |
| Dee Sparacio @womenofteal RT @ASCO: T3: T3: More trials are incorporating PROs so outcomes can be measured against pts’ needs/interests https://t.co/L02FN4tcgW #gyncsm |
| Kathleen Maxian @KathleenMaxian RT @ASCO: T3: T3: More trials are incorporating PROs so outcomes can be measured against pts’ needs/interests https://t.co/L02FN4tcgW #gyncsm |
| ASCO @ASCO T3: Research has shown that when patients self-report symptoms, they have better outcomes https://t.co/cjl8npOxVE #gyncsm |
| Kathleen Maxian @KathleenMaxian RT @ASCO: T3: T3: Research has shown that when patients self-report symptoms, they have better outcomes https://t.co/cjl8npOxVE #gyncsm |
| Dee Sparacio @womenofteal RT @ASCO: T3: T3: Research has shown that when patients self-report symptoms, they have better outcomes https://t.co/cjl8npOxVE #gyncsm |
 | Educate-TV @educate_tv RT @ASCO: T1: T1: New trial designs let us study multiple cancers/treatments at the same time & learn which therapy works best for each patient #gyncsm |
| Christina Lizaso @btrfly12 RT @ASCO: T3: T3: Research has shown that when patients self-report symptoms, they have better outcomes https://t.co/cjl8npOxVE #gyncsm |
| Enlightening Results 💡 @GraceCordovano Hi #gyncsm! Grace, private cancer patient advocate, joining late from NJ |
| Suzie Siegel @SuzieSiegel .@crazyknit68 bring up an important issue about coop groups. Wasn't GOG combined with SWOG? R we seeing fewer trials? #gyncsm |
 | Lisa Fields @lisafieldsms RT @ASCO: T3: T3: Research has shown that when patients self-report symptoms, they have better outcomes https://t.co/cjl8npOxVE #gyncsm |
| Enlightening Results 💡 @GraceCordovano RT @ASCO: T3: T3: PROs are anything reported directly by the patient, like symptoms or emotions. They reflect how patients feel & function #gyncsm |
| Dee Sparacio @womenofteal @ASCO Good to see these PRO results reported during presentations on reserarch at the annual meeting. #gyncsm |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba T3 PROs are the consequences or benefit from a treatment plan, as reported by the patient. #gyncsm |
| Dee Sparacio @womenofteal RT @ShereesePubHlth: T3 PROs are the consequences or benefit from a treatment plan, as reported by the patient. #gyncsm |
| Tobey @BRCAinfo RT @ASCO: T3: T3: Research has shown that when patients self-report symptoms, they have better outcomes https://t.co/cjl8npOxVE #gyncsm |
| Christina Lizaso @btrfly12 @GraceCordovano great to see you :) #gyncsm |
| Ovarian Cancer Proj @WNYOCP RT @ASCO: T3: T3: Research has shown that when patients self-report symptoms, they have better outcomes https://t.co/cjl8npOxVE #gyncsm |
| Christina Lizaso @btrfly12 RT @womenofteal: @ASCO Good to see these PRO results reported during presentations on reserarch at the annual meeting. #gyncsm |
| Dee Sparacio @womenofteal T3 @theNCI article https://t.co/Q44Erv4LLP #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin T3: PROS - patient reported outcomes help determine the impact novel treatments in a clinical trial have on #QOL (quality of life) #gyncsm |
| Janet Freeman-Daily @JFreemanDaily @SuzieSiegel Yes--#ROS1 fusions occur in 8+ cancers (including ovarian), but crizotinib is currently approved for only NSCLC. Tapur is option. #gyncsm |
| Jen Burzawa @jburzawa RT @ShannonWestin: T3: T3: PROS - patient reported outcomes help determine the impact novel treatments in a clinical trial have on #QOL (quality of life) #gyncsm |
| Ovarian Cancer Proj @WNYOCP RT @ASCO: T3: T3: More trials are incorporating PROs so outcomes can be measured against pts’ needs/interests https://t.co/L02FN4tcgW #gyncsm |
| ASCO @ASCO @womenofteal This particular study was highlighted in our Plenary Session - it was a big deal! #gyncsm |
| Christina Lizaso @btrfly12 RT @ShannonWestin: T3: T3: PROS - patient reported outcomes help determine the impact novel treatments in a clinical trial have on #QOL (quality of life) #gyncsm |
| Ovarian Cancer Proj @WNYOCP RT @womenofteal: T2 more info on TAPUR on @cancerdotnet https://t.co/s6tr25n2Nb #gyncsm |
| Jen Burzawa @jburzawa RT @ASCO: T3: T3: Research has shown that when patients self-report symptoms, they have better outcomes https://t.co/cjl8npOxVE #gyncsm |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba @GraceCordovano #gyncsm https://t.co/HNMSdMrMXR |
| GYN Cancer | #GYNCSM @gyncsm Topic 4 in two parts (T4a: and T4b:) coming up... https://t.co/p9Ngbc9iw7 #gyncsm |
| Dr. Lisa Aiello @aiellolisa136 @SuzieSiegel good question about what coop groups are doing now. Not sure. #gyncsm |
| Enlightening Results 💡 @GraceCordovano @ASCO Outcomes significantly better than some newly approved therapies. Must use #tech to meet the patient. #gyncsm |
| Dee Sparacio @womenofteal The National Quality forum reported on PROs https://t.co/6HH8FiWWyq #gyncsm |
| Suzie Siegel @SuzieSiegel T3. Some women don't want to complain. We need to convince them that it's good to report all symptoms. #gyncsm |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba RT @womenofteal: The National Quality forum reported on PROs https://t.co/6HH8FiWWyq #gyncsm |
| Enlightening Results 💡 @GraceCordovano @ShereesePubHlth Hi Love! How are you tonight #gyncsm |
| Christina Lizaso @btrfly12 RT @SuzieSiegel: T3. Some women don't want to complain. We need to convince them that it's good to report all symptoms. #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters Self-reporting symptoms can serve to make patients feel more involved and they may be more open to sharing symptoms. This is great! #gyncsm https://t.co/jjMtIP2fVk |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @RieOfLetters: Self-reporting symptoms can serve to make patients feel more involved and they may be more open to sharing symptoms. This is great! #gyncsm https://t.co/jjMtIP2fVk |
| Enlightening Results 💡 @GraceCordovano RT @ASCO: T3: T3: More trials are incorporating PROs so outcomes can be measured against pts’ needs/interests https://t.co/L02FN4tcgW #gyncsm |
| Janet Freeman-Daily @JFreemanDaily T3: Some studies found PROs (Patient Reported Outcomes) focus on different quality of life measures than clinicians tend to choose. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T4a: Have you been involved in a #clinicaltrial? #gyncsm |
| Enlightening Results 💡 @GraceCordovano @btrfly12 Hi Christina! Hope you are doing well #gyncsm |
| Dr. Lisa Aiello @aiellolisa136 @JFreemanDaily important point #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters Saving to read this later! https://t.co/Br03EfHzIz |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba @GraceCordovano Exhausted but w/ good cause. Just convinced a Med org 2 adopt a Pt leadership board (PAC). I'm going to mentor until up & running #gyncsm |
| Dee Sparacio @womenofteal @JFreemanDaily Yes we need to change that so we are on the same page #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T4a: T4a: Have you been involved in a #clinicaltrial? #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @JFreemanDaily: T3: T3: Some studies found PROs (Patient Reported Outcomes) focus on different quality of life measures than clinicians tend to choose. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @RieOfLetters: Self-reporting symptoms can serve to make patients feel more involved and they may be more open to sharing symptoms. This is great! #gyncsm https://t.co/jjMtIP2fVk |
| Dee Sparacio @womenofteal RT @SuzieSiegel: T3. Some women don't want to complain. We need to convince them that it's good to report all symptoms. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @SuzieSiegel: T3. Some women don't want to complain. We need to convince them that it's good to report all symptoms. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @ASCO: T3: T3: Research has shown that when patients self-report symptoms, they have better outcomes https://t.co/cjl8npOxVE #gyncsm |
| Enlightening Results 💡 @GraceCordovano @ShannonWestin Critically important to include & capture. Preferred Dr outcomes vs patient outcomes sometimes don't align #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @GraceCordovano: @ASCO Outcomes significantly better than some newly approved therapies. Must use #tech to meet the patient. #gyncsm |
| Janet Freeman-Daily @JFreemanDaily T4a: My cancer progressed after two different lines of chemo/rads. Targeted therapy clinical trial had me NED at first scan! #gyncsm |
| Georgia Hurst @shewithlynch RT @SuzieSiegel: T1: T1: It's important for patients to understand that #clinicaltrials are NOT the treatment of last resort. #gyncsm | |
| Enlightening Results 💡 @GraceCordovano @SuzieSiegel Need to have safe environment to do so. Many afraid of reporting side effects and impact on trial participation #gyncsm |
| Dr. Lisa Aiello @aiellolisa136 @gyncsm T4 my brother was in a clinical trial for stage 4 colon cancer. It looked at EGFR+ drugs +/- avastin #gyncsm |
| Georgia Hurst @shewithlynch RT @EMBOSU: A bit late, I'm Erica, genetic counselor at @MDAndersonNews with a focus on hereditary gyn cancers #gyncsm https://t.co/ge583b9mxb | |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin @GraceCordovano Agree - its important to balance both - especially if there are multiple treatment options #gyncsm |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba RT @JFreemanDaily: T4a: T4a: My cancer progressed after two different lines of chemo/rads. Targeted therapy clinical trial had me NED at first scan! #gyncsm |
| Christina Lizaso @btrfly12 T3a: I've participated in some interview studies and am signing up for PROMPT re:l genetic variants related to cancer. #gyncsm |
| Suzie Siegel @SuzieSiegel T4a. I wasn't enrolled in the Gemzar/Taxotere trial for uterine #leiomyosarcoma but my CR was real-world evidence. #gyncsm |
| Georgia Hurst @shewithlynch RT @gyncsm: T4a: T4a: Have you been involved in a #clinicaltrial? #gyncsm | |
| Georgia Hurst @shewithlynch RT @RieOfLetters: Self-reporting symptoms can serve to make patients feel more involved and they may be more open to sharing symptoms. This is great! #gyncsm https://t.co/jjMtIP2fVk | |
| GYN Cancer | #GYNCSM @gyncsm T4b: If yes, what benefits or drawbacks did you experience? If no, what were some of the reasons? Were trials offered to you? #gyncsm |
| Georgia Hurst @shewithlynch RT @SuzieSiegel: T3. Some women don't want to complain. We need to convince them that it's good to report all symptoms. #gyncsm | |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin T4a: I have been involved as an investigator in #clinicaltrials for years! Have never participated in one - but I would!! #gyncsm |
| Dee Sparacio @womenofteal T4a I was in a phase 1 on intitial DX for OC. I also have - or rather my tumor tissue has been in a few other trials #gyncsm |
| Georgia Hurst @shewithlynch RT @womenofteal: The National Quality forum reported on PROs https://t.co/6HH8FiWWyq #gyncsm | |
| Janet Freeman-Daily @JFreemanDaily T4: Also signed up for clinical study to collect my tumor tissue (should my cancer progress) and make cancer models from it. #gyncsm |
| Georgia Hurst @shewithlynch RT @GraceCordovano: @ASCO Outcomes significantly better than some newly approved therapies. Must use #tech to meet the patient. #gyncsm | |
| Jen Burzawa @jburzawa RT @ShannonWestin: T4a: T4a: I have been involved as an investigator in #clinicaltrials for years! Have never participated in one - but I would!! #gyncsm |
| Georgia Hurst @shewithlynch RT @ShannonWestin: T3: T3: PROS - patient reported outcomes help determine the impact novel treatments in a clinical trial have on #QOL (quality of life) #gyncsm | |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba T4 Not I. If cancer tx & therapies are going to be anything, they ought to begin by being precise. Clinical trials help to that end #gyncsm |
| Georgia Hurst @shewithlynch RT @womenofteal: T3 @theNCI article https://t.co/Q44Erv4LLP #gyncsm | |
| Dee Sparacio @womenofteal RT @gyncsm: T4b: T4b: If yes, what benefits or drawbacks did you experience? If no, what were some of the reasons? Were trials offered to you? #gyncsm |
| Merry-Jennifer Markham, MD, FACP, FASCO @DrMarkham Same. :) #gyncsm https://t.co/pRVhYWNNmz |
| Georgia Hurst @shewithlynch RT @ShereesePubHlth: T3 PROs are the consequences or benefit from a treatment plan, as reported by the patient. #gyncsm | |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin @JFreemanDaily These tissue studies are so important! Thank you #gyncsm |
| Georgia Hurst @shewithlynch RT @ShannonWestin: @crazyknit68 @ASCO Yes - @ASCO is an advocacy group for cancer patients and physicians - its awesome they are running a trial #gyncsm | |
| Dee Sparacio @womenofteal T4b I had a trial nurse on speed dial for any issues questions I had in that first trial. Lots of follow-up too. #gyncsm |
| Janet Freeman-Daily @JFreemanDaily T1b: Benefits of trials: receive AT LEAST standard of care, see top cancer docs, might help future patients as well as yourself #gyncsm |
| Georgia Hurst @shewithlynch RT @btrfly12: Several years ago Susan Gubar wrote about the Rainbow Coalition - as the organ of origin starts to matter less in cancer treatment #gyncsm | |
| Enlightening Results 💡 @GraceCordovano @JFreemanDaily Wow! That is incredible! 💕 #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters @SuzieSiegel Yes! I think it will require a cultural shift towards believing women and empowering them. Progress is slow, but it's changing. #gyncsm |
| Georgia Hurst @shewithlynch RT @ASCO: T2: Our CMO @rschilsky and Past Pres. @DrJulieVose explain why ASCO developed the TAPUR study in this video: T2: Our CMO @rschilsky and Past Pres. @DrJulieVose explain why ASCO developed the TAPUR study in this video: https://t.co/j9qEuIY3tY #gyncsm | |
| Christina Lizaso @btrfly12 T4b: I'd love the chance to be more closely monitored but also, as CHEK2 isn't well studied yet, hope can be part of figuring it out #gyncsm |
| Janet Freeman-Daily @JFreemanDaily T1b: Drawbacks of trials: hard to find "best" trial for you, may require travel & time away from family, varying level of risk #gyncsm |
| Erica Bednar @EMBOSU RT @JFreemanDaily: T1b: Benefits of trials: T1b: Benefits of trials: receive AT LEAST standard of care, see top cancer docs, might help future patients as well as yourself #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin @garmischgirl This is a huge issue - we are trying to make it easier for patients to find trials as part of an @SGO_org initiative #gyncsm |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: T1b: Benefits of trials: T1b: Benefits of trials: receive AT LEAST standard of care, see top cancer docs, might help future patients as well as yourself #gyncsm |
| Dee Sparacio @womenofteal @JFreemanDaily And you were instrumental in finding a study you could participate in. #gyncsm |
 | Amy Byer Shainman @BRCAresponder RT @LguzzardiM: #HereditaryCancerNews #gyncsm #genetictesting #BRCA #Genetics #familyhistory #prevention https://t.co/BcV3cgWGpE |
| Georgia Hurst @shewithlynch RT @LguzzardiM: #Genetictesting helps identify #hereditarycancer syndromes #BRCA #VUS #GINA #HBOC #bcsm #gyncsm @masslivenews https://t.co/QC5fcf2n2L | |
| Jillosopher, BSN, RN @jillosopher T4b not offered. Have asked onc about using AI to prevent recurrence. Answer: not studied. Me: R U studying? Ans: no. frustrating #gyncsm |
| Dee Sparacio @womenofteal RT @ShannonWestin: @garmischgirl This is a huge issue - we are trying to make it easier for patients to find trials as part of an @SGO_org initiative #gyncsm |
| Ovarian Cancer Proj @WNYOCP RT @JFreemanDaily: T1b: Benefits of trials: T1b: Benefits of trials: receive AT LEAST standard of care, see top cancer docs, might help future patients as well as yourself #gyncsm |
| Dee Sparacio @womenofteal RT @LguzzardiM: #Genetictesting helps identify #hereditarycancer syndromes #BRCA #VUS #GINA #HBOC #bcsm #gyncsm @masslivenews https://t.co/QC5fcf2n2L |
| Ovarian Cancer Proj @WNYOCP RT @LguzzardiM: #Genetictesting helps identify #hereditarycancer syndromes #BRCA #VUS #GINA #HBOC #bcsm #gyncsm @masslivenews https://t.co/QC5fcf2n2L |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: T1b: Drawbacks of trials: T1b: Drawbacks of trials: hard to find "best" trial for you, may require travel & time away from family, varying level of risk #gyncsm |
| Dr. Lisa Aiello @aiellolisa136 @gyncsm my brother did well on trial, extended his life. trial helped clarify treatment. Brother also saw altruistic benefits #gyncsm |
| Tobey @BRCAinfo @garmischgirl That’s really a shame. Researchers should involve lay people or advocates to get the word out re #clinicaltrials #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @BRCAinfo: @garmischgirl That’s really a shame. Researchers should involve lay people or advocates to get the word out re #clinicaltrials #gyncsm |
| Tobey @BRCAinfo RT @JFreemanDaily: T1b: Benefits of trials: T1b: Benefits of trials: receive AT LEAST standard of care, see top cancer docs, might help future patients as well as yourself #gyncsm |
| Suzie Siegel @SuzieSiegel @gyncsm The benefit of doing study drugs outside a #clinicaltrial was my Drs had more room to change the protocol. #gyncsm |
| Georgia Hurst @shewithlynch RT @ShannonWestin: @garmischgirl This is a huge issue - we are trying to make it easier for patients to find trials as part of an @SGO_org initiative #gyncsm | |
| GYN Cancer | #GYNCSM @gyncsm @e_darcelle thanks for joining along and sharing. best wishes as you begin your trial. #gyncsm |
| Georgia Hurst @shewithlynch RT @BRCAinfo: @garmischgirl That’s really a shame. Researchers should involve lay people or advocates to get the word out re #clinicaltrials #gyncsm | |
 | Technology Coaching @techcoachinguk RT @GraceCordovano: @ASCO Outcomes significantly better than some newly approved therapies. Must use #tech to meet the patient. #gyncsm |
| Janet Freeman-Daily @JFreemanDaily @womenofteal Yes, I learned about clinical trial options, molecular tumor testing, and ROS1 fusions from other online patients. #gyncsm |
| Enlightening Results 💡 @GraceCordovano @garmischgirl Must be your own advocate. But @CancerResearch has navigators ready to help pts find immunotherapy trials. ##gyncsm |
| Dee Sparacio @womenofteal @e_darcelle Good luck . #gyncsm |
| Georgia Hurst @shewithlynch RT @JFreemanDaily: T1b: Drawbacks of trials: T1b: Drawbacks of trials: hard to find "best" trial for you, may require travel & time away from family, varying level of risk #gyncsm | |
| Ann Becker-Schutte @DrBeckerSchutte RT @JFreemanDaily: @womenofteal Yes, I learned about clinical trial options, molecular tumor testing, and ROS1 fusions from other online patients. #gyncsm |
| Dee Sparacio @womenofteal RT @GraceCordovano: @garmischgirl Must be your own advocate. But @CancerResearch has navigators ready to help pts find immunotherapy trials. ##gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @GraceCordovano: @garmischgirl Must be your own advocate. But @CancerResearch has navigators ready to help pts find immunotherapy trials. ##gyncsm |
| Georgia Hurst @shewithlynch RT @RieOfLetters: @btrfly12 Immunotherapy is definitely trending as a treatment for many types of cancer and it is only in its infancy. Exciting! #gyncsm | |
| Ann Becker-Schutte @DrBeckerSchutte RT @crazyknit68: @gyncsm my brother did well on trial, extended his life. trial helped clarify treatment. Brother also saw altruistic benefits #gyncsm |
| Dee Sparacio @womenofteal RT @SuzieSiegel: @gyncsm The benefit of doing study drugs outside a #clinicaltrial was my Drs had more room to change the protocol. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @jillosopher: T4b not offered. Have asked onc about using AI to prevent recurrence. Answer: not studied. Me: R U studying? Ans: T4b not offered. Have asked onc about using AI to prevent recurrence. Answer: not studied. Me: R U studying? Ans: no. frustrating #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @ShannonWestin: @garmischgirl This is a huge issue - we are trying to make it easier for patients to find trials as part of an @SGO_org initiative #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @JFreemanDaily: T1b: Drawbacks of trials: T1b: Drawbacks of trials: hard to find "best" trial for you, may require travel & time away from family, varying level of risk #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @btrfly12: T4b: T4b: I'd love the chance to be more closely monitored but also, as CHEK2 isn't well studied yet, hope can be part of figuring it out #gyncsm |
| Enlightening Results 💡 @GraceCordovano @ShereesePubHlth Bravo! Keep chipping away! Thanks for all you do. Hope the little one is feeling better #gyncsm |
| Dr. Lisa Aiello @aiellolisa136 @gyncsm T4b Trial was offered. Doc active researcher Axel Grothey. Seems offering trial is based on MD. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte @garmischgirl @womenofteal @JFreemanDaily I have gotten the impression that trial info can be very territorial. #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters @crazyknit68 @gyncsm My grandfather participated in many clinical trials and it gave him a better quality of life. Altruism was a big motivating factor #gyncsm |
| Suzie Siegel @SuzieSiegel T4. A lot of doctors mention only the #clinicaltrials at their hospital. #gyncsm |
| Janet Freeman-Daily @JFreemanDaily @garmischgirl @womenofteal FAR too many trials at too many locations for any one doc to track. Clinical trial finders help. #gyncsm |
| Christina Lizaso @btrfly12 Patient communities continue to be one of the best places to find out about trials. There are groups trying to make it easier #gyncsm |
 | Dr. Wanda Montalvo PhD, RN, FAAN @Montalvo501 RT @RieOfLetters: Self-reporting symptoms can serve to make patients feel more involved and they may be more open to sharing symptoms. This is great! #gyncsm https://t.co/jjMtIP2fVk |
| Janet Freeman-Daily @JFreemanDaily RT @btrfly12: Patient communities continue to be one of the best places to find out about trials. There are groups trying to make it easier #gyncsm |
| Tobey @BRCAinfo RT @DrBeckerSchutte: @garmischgirl @womenofteal @JFreemanDaily I have gotten the impression that trial info can be very territorial. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte @SuzieSiegel T4: I think that this is sometimes to get their trials filled and sometimes because they lack info/access to others. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @JFreemanDaily: @garmischgirl @womenofteal FAR too many trials at too many locations for any one doc to track. Clinical trial finders help. #gyncsm |
| Dr. Wanda Montalvo PhD, RN, FAAN @Montalvo501 RT @ShannonWestin: T3: T3: PROS - patient reported outcomes help determine the impact novel treatments in a clinical trial have on #QOL (quality of life) #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @btrfly12: Patient communities continue to be one of the best places to find out about trials. There are groups trying to make it easier #gyncsm |
| Tobey @BRCAinfo @DrBeckerSchutte @garmischgirl @womenofteal @JFreemanDaily Totally agree -#gyncsm |
| Suzie Siegel @SuzieSiegel T4. @CureSarcoma helps #sarcoma patients navigate clinical trials. #gyncsm |
| Christina Lizaso @btrfly12 I keep this Twitter list of start-ups and others trying to make finding trials easier: https://t.co/oEBuzDxPvh #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Last topic (T5:) coming up... https://t.co/p9Ngbc9iw7 #gyncsm |
| Merry-Jennifer Markham, MD, FACP, FASCO @DrMarkham And can always search here: https://t.co/q85sxm1vzC That's how I find trials not at my institution. #gyncsm https://t.co/RNXoNZRFtZ |
| Janet Freeman-Daily @JFreemanDaily @btrfly12 Online patient communities focused on your cancer are often best place to learn about clinical trials for you. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @DrMarkham: And can always search here: And can always search here: https://t.co/q85sxm1vzC That's how I find trials not at my institution. #gyncsm https://t.co/RNXoNZRFtZ |
| Dee Sparacio @womenofteal @garmischgirl @JFreemanDaily Hard for a doc to know about all the trials - there are so many of them. Helps if NCI comp cancer ctr #gyncsm |
| Christina Lizaso @btrfly12 Some nonprofits like for Pancreatic Cancer are very on top of things w/ tumor profiling and finders. Love to see better for gyn #gyncsm |
| Ovarian Cancer Proj @WNYOCP The @WNYOCP will help you find #ovariancancer #clinicaltrials #gyncsm https://t.co/qXU3yjGIUo |
| Dee Sparacio @womenofteal RT @btrfly12: Patient communities continue to be one of the best places to find out about trials. There are groups trying to make it easier #gyncsm |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: @btrfly12 Online patient communities focused on your cancer are often best place to learn about clinical trials for you. #gyncsm |
| Dee Sparacio @womenofteal RT @btrfly12: I keep this Twitter list of start-ups and others trying to make finding trials easier: I keep this Twitter list of start-ups and others trying to make finding trials easier: https://t.co/oEBuzDxPvh #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T5: Per @SGO_org, there is a crisis in gyn cancer trials. How can #gyncsm support research and encourage participation in #clinicaltrials? |
| Rie Lopez, MPH (she/her) @RieOfLetters RT @btrfly12: I keep this Twitter list of start-ups and others trying to make finding trials easier: I keep this Twitter list of start-ups and others trying to make finding trials easier: https://t.co/oEBuzDxPvh #gyncsm |
| Dee Sparacio @womenofteal RT @JFreemanDaily: @btrfly12 Online patient communities focused on your cancer are often best place to learn about clinical trials for you. #gyncsm |
| Jen Burzawa @jburzawa RT @btrfly12: I keep this Twitter list of start-ups and others trying to make finding trials easier: I keep this Twitter list of start-ups and others trying to make finding trials easier: https://t.co/oEBuzDxPvh #gyncsm |
| Dee Sparacio @womenofteal RT @WNYOCP: The @WNYOCP will help you find #ovariancancer #clinicaltrials #gyncsm https://t.co/qXU3yjGIUo |
| Dee Sparacio @womenofteal RT @gyncsm: T5: T5: Per @SGO_org, there is a crisis in gyn cancer trials. How can #gyncsm support research and encourage participation in #clinicaltrials? |
| Rie Lopez, MPH (she/her) @RieOfLetters RT @DrMarkham: And can always search here: And can always search here: https://t.co/q85sxm1vzC That's how I find trials not at my institution. #gyncsm https://t.co/RNXoNZRFtZ |
| Suzie Siegel @SuzieSiegel Because of #sarcoma & gynonc silos, women with sarcoma may not hear about trials run by different docs. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Resource | Gyn Trials Crisis Fact Sheet from @SGOorg https://t.co/3vsXKWKeO8 #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin T5: #gyncsm can continue great advocacy work and spread the word about the benefit of #clinicaltrials |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @gyncsm: Resource | Gyn Trials Crisis Fact Sheet from @SGOorg https://t.co/3vsXKWKeO8 #gyncsm |
| ASCO @ASCO T5: Educate yourself & share info with others! Online patient communities & chats like this one are a great start #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @ASCO: T5: T5: Educate yourself & share info with others! Online patient communities & chats like this one are a great start #gyncsm |
| Tobey @BRCAinfo RT @DrMarkham: And can always search here: And can always search here: https://t.co/q85sxm1vzC That's how I find trials not at my institution. #gyncsm https://t.co/RNXoNZRFtZ |
| Enlightening Results 💡 @GraceCordovano Dear patients: this 👇🏻👇🏻 #gyncsm https://t.co/h1NfmJI26g |
| Jillosopher, BSN, RN @jillosopher RT @btrfly12: Some nonprofits like for Pancreatic Cancer are very on top of things w/ tumor profiling and finders. Love to see better for gyn #gyncsm |
| Dr. Lisa Aiello @aiellolisa136 T4b. Research shows minorities R offered CT less. Therefore don't know best treatment 4 minorities. genomic focus may improve this #gyncsm |
| Janet Freeman-Daily @JFreemanDaily T5: Find ways to help more #gyncsm patients get molecular testing and join "basket trials" for any solid tumor type. |
| GYN Cancer | #GYNCSM @gyncsm Resource | Gyn Trials Crisis Fact Sheet from @SGO_org https://t.co/M4EXOS2iYA… #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @btrfly12: Patient communities continue to be one of the best places to find out about trials. There are groups trying to make it easier #gyncsm |
| ASCO @ASCO T5 @CancerDotNet has great resources on clinical trials: https://t.co/dZmeQRfKSF #gyncsm |
| Dee Sparacio @womenofteal T5 Here is the chart @SGO_org has on trials #gyncsm https://t.co/c9Y0sGBB38 |
 | Liz Cramer @oncELLEogy RT @JFreemanDaily: T4a: T4a: My cancer progressed after two different lines of chemo/rads. Targeted therapy clinical trial had me NED at first scan! #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @ASCO: T5 @CancerDotNet has great resources on clinical trials: T5 @CancerDotNet has great resources on clinical trials: https://t.co/dZmeQRfKSF #gyncsm |
| Dee Sparacio @womenofteal RT @ASCO: T5 @CancerDotNet has great resources on clinical trials: T5 @CancerDotNet has great resources on clinical trials: https://t.co/dZmeQRfKSF #gyncsm |
| ASCO @ASCO T5: Contact your lawmakers & urge them to support research by increasing funding for @NIH and @theNCI https://t.co/wdl5tla4TA #gyncsm |
| Merry-Jennifer Markham, MD, FACP, FASCO @DrMarkham RT @ASCO: T5: T5: Contact your lawmakers & urge them to support research by increasing funding for @NIH and @theNCI https://t.co/wdl5tla4TA #gyncsm |
| Ovarian Cancer Proj @WNYOCP RT @ASCO: T5: T5: Educate yourself & share info with others! Online patient communities & chats like this one are a great start #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters RT @GraceCordovano: Dear patients: Dear patients: this 👇🏻👇🏻 #gyncsm https://t.co/h1NfmJI26g |
| Dee Sparacio @womenofteal RT @JFreemanDaily: T5: T5: Find ways to help more #gyncsm patients get molecular testing and join "basket trials" for any solid tumor type. |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba @GraceCordovano he went back to school today. Thanks #gyncsm |
| Dee Sparacio @womenofteal RT @ASCO: T5: T5: Educate yourself & share info with others! Online patient communities & chats like this one are a great start #gyncsm |
| Dee Sparacio @womenofteal RT @ASCO: T5: T5: Contact your lawmakers & urge them to support research by increasing funding for @NIH and @theNCI https://t.co/wdl5tla4TA #gyncsm |
| Janet Freeman-Daily @JFreemanDaily T5: Provide resources that support patient travel to clinical trials and provide supports at home during travel. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin T5: Important to advocate for MORE research funding for the @NIH and @theNCI - more funds = more trials. Call your congressman! #gyncsm |
| Christina Lizaso @btrfly12 I'll take this opportunity to thank @asco for all the amazing resources for patients on @cancerdotnet #gyncsm |
| Dee Sparacio @womenofteal RT @JFreemanDaily: T5: T5: Provide resources that support patient travel to clinical trials and provide supports at home during travel. #gyncsm |
| Dr. Lisa Aiello @aiellolisa136 @gyncsm @SGO_org So crisis is less Gyn specific trials? Why? #gyncsm |
| Christina Lizaso @btrfly12 RT @ShannonWestin: T5: T5: Important to advocate for MORE research funding for the @NIH and @theNCI - more funds = more trials. Call your congressman! #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @ShannonWestin: T5: T5: Important to advocate for MORE research funding for the @NIH and @theNCI - more funds = more trials. Call your congressman! #gyncsm |
| Ovarian Cancer Proj @WNYOCP Here @WNYOCP we know our members who r #ovariancancer patients do better because they are educated about their disease #gyncsm https://t.co/tlRDzg9sgo |
| Ann Becker-Schutte @DrBeckerSchutte RT @ASCO: T5: T5: Contact your lawmakers & urge them to support research by increasing funding for @NIH and @theNCI https://t.co/wdl5tla4TA #gyncsm |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: T5: T5: Find ways to help more #gyncsm patients get molecular testing and join "basket trials" for any solid tumor type. |
| Ann Becker-Schutte @DrBeckerSchutte RT @womenofteal: T5 Here is the chart @SGO_org has on trials #gyncsm https://t.co/c9Y0sGBB38 |
| Ann Becker-Schutte @DrBeckerSchutte RT @gyncsm: Resource | Gyn Trials Crisis Fact Sheet from @SGO_org https://t.co/M4EXOS2iYA… #gyncsm |
| Suzie Siegel @SuzieSiegel @gyncsm @SGO_org It was NRG that swallowed GOG, not SWOG. #gyncsm |
| Christina Lizaso @btrfly12 RT @crazyknit68: T4b. Research shows minorities R offered CT less. Therefore don't know best treatment 4 minorities. genomic focus may improve this #gyncsm |
| Christina Lizaso @btrfly12 RT @ASCO: T5: T5: Educate yourself & share info with others! Online patient communities & chats like this one are a great start #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters Yes! I see so many great advocates here that I have met through other #clinicaltrial and health-related chats. You are all amazing! #gyncsm https://t.co/xzKTax0O14 |
| Ann Becker-Schutte @DrBeckerSchutte So critical. We have to speak out. RT @temkins T5: Call your congress person. #gyncsm https://t.co/M7OQ6hUf72 |
| Janet Freeman-Daily @JFreemanDaily T5: Consider having your #gyncsm tumor undergo broad genomic testing to help researchers identify targetable genomic drivers. |
| Christina Lizaso @btrfly12 RT @SuzieSiegel: Because of #sarcoma & gynonc silos, women with sarcoma may not hear about trials run by different docs. #gyncsm |
| Christina Lizaso @btrfly12 RT @WNYOCP: The @WNYOCP will help you find #ovariancancer #clinicaltrials #gyncsm https://t.co/qXU3yjGIUo |
| Ann Becker-Schutte @DrBeckerSchutte RT @JFreemanDaily: T5: T5: Consider having your #gyncsm tumor undergo broad genomic testing to help researchers identify targetable genomic drivers. |
| Dr. Lisa Aiello @aiellolisa136 @ASCO @NIH @theNCI Crisis is primarily due to lack of funding? #gyncsm |
| Christina Lizaso @btrfly12 @ClearityFnd can help with tumor profiling for #ovariancancer - #gyncsm |
| Jillosopher, BSN, RN @jillosopher Yes! one week my thought-to-be early stage endometrial ca turns out to be stage 3a. Next week, receiving chemo. No time to think. #gyncsm https://t.co/oDVGPG9oPU |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin @crazyknit68 @gyncsm @SGO_org The combined cooperative groups means that the money is divided by three - this means less trials per group #gyncsm |
| Dee Sparacio @womenofteal Agree! women don't have BRCA testing done after dx MT @JFreemanDaily: T5: Consider having your #gyncsm tumor undergo broad genomic testing |
| Dee Sparacio @womenofteal RT @btrfly12: @ClearityFnd can help with tumor profiling for #ovariancancer - #gyncsm |
| Janet Freeman-Daily @JFreemanDaily @DrBeckerSchutte @garmischgirl @womenofteal Some (not all) clinicians may promote trials at THEIR facility over trials available nearby or at more distant facilities. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Great chat tonight. Time to start sharing closing thoughts. You can start ur tweet w/ “TIL:” standing for Today I Learned... #gyncsm |
| Dee Sparacio @womenofteal @garmischgirl Have you had genetic testing? #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Great chat tonight. Time to start sharing closing thoughts. You can start ur tweet w/ “TIL:” standing for Today I Learned... #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin @JFreemanDaily @DrBeckerSchutte @garmischgirl @womenofteal Some of it may be territoriality - some of it may be lack of knowledge of what else is out there #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @JFreemanDaily: @DrBeckerSchutte @garmischgirl @womenofteal Some (not all) clinicians may promote trials at THEIR facility over trials available nearby or at more distant facilities. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @ShannonWestin: @JFreemanDaily @DrBeckerSchutte @garmischgirl @womenofteal Some of it may be territoriality - some of it may be lack of knowledge of what else is out there #gyncsm |
 | Mary Tyler Less 🕊️ @THEJargonSlayer RT @ASCO: T5: T5: Contact your lawmakers & urge them to support research by increasing funding for @NIH and @theNCI https://t.co/wdl5tla4TA #gyncsm |
| Dee Sparacio @womenofteal @crazyknit68 @ASCO @NIH @theNCI More funding will help for sure #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @gyncsm: Great chat tonight. Time to start sharing closing thoughts. You can start ur tweet w/ “TIL:” standing for Today I Learned... #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm We are so appreciative of @ASCO for taking time to share information on #gyncsm chat tonight. Thanks for all you do for patients. |
 | Gaye Walker @gayewalker RT @ASCO: T2: Our CMO @rschilsky and Past Pres. @DrJulieVose explain why ASCO developed the TAPUR study in this video: T2: Our CMO @rschilsky and Past Pres. @DrJulieVose explain why ASCO developed the TAPUR study in this video: https://t.co/j9qEuIY3tY #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @gyncsm: We are so appreciative of @ASCO for taking time to share information on #gyncsm chat tonight. Thanks for all you do for patients. |
| Ann Becker-Schutte @DrBeckerSchutte TIL: There is so much I still don't know about the intricacies of clinical trials. #gyncsm |
| Janet Freeman-Daily @JFreemanDaily @DrMarkham https://t.co/Xu17kYwsoh helps, but requires patient to know lingo, and may generate LONG list of results w/no way to choose "best." #gyncsm |
| Dee Sparacio @womenofteal Thank you @ASCO for participating! #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm We also greatly appreciate all clinical trial participants - past, present and future - for your amazing contributions to medicine #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @gyncsm: We also greatly appreciate all clinical trial participants - past, present and future - for your amazing contributions to medicine #gyncsm |
| Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba RT @gyncsm: We also greatly appreciate all clinical trial participants - past, present and future - for your amazing contributions to medicine #gyncsm |
| Suzie Siegel @SuzieSiegel It would be great if all #gyncsm resources mentioned #sarcoma. We would be grateful for even one link. |
 | Beth Caldwell @CultPerfectMoms RT @womenofteal: Agree! women don't have BRCA testing done after dx MT @JFreemanDaily: T5: Agree! women don't have BRCA testing done after dx MT @JFreemanDaily: T5: Consider having your #gyncsm tumor undergo broad genomic testing |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin @JFreemanDaily @DrMarkham @SGO_org working on a #gyncsm specific #clinicaltrial search engine that we hope will simplify the process |
| Erica Bednar @EMBOSU Testing gyn cancer for BRCA (tumor testing) has different implications than testing blood/saliva (hereditary genetic testing) #gyncsm https://t.co/aNtKVB830g |
| Tobey @BRCAinfo TIL 👍 Great group of people tonight on the #gyncsm chat 👏👏👏 #clinicaltrials are changing for the better. We still need to get the word out |
| Merry-Jennifer Markham, MD, FACP, FASCO @DrMarkham Taking this info to the oncologist, or working with oncologist to search appropriately is key. https://t.co/KU9xaL473O |
| Jillosopher, BSN, RN @jillosopher TIL I have much to learn about clinical trials #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @BRCAinfo: TIL 👍 Great group of people tonight on the #gyncsm chat 👏👏👏 #clinicaltrials are changing for the better. We still need to get the word out |
| Dr. Lisa Aiello @aiellolisa136 TIL about new paradigm of research studies, specifically related to genomic tumor markers, and ASCO as sponsor instead of coop group #gyncsm |
| Enlightening Results 💡 @GraceCordovano TIL: PRO are not a nice to have, they are a must in clinical trial design. #gyncsm |
| Dee Sparacio @womenofteal TIL Since DX the cliincal trial landscape has changed but there is still a need to improve access to more patients & rpt PROS. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @DrMarkham: Taking this info to the oncologist, or working with oncologist to search appropriately is key. https://t.co/KU9xaL473O |
| Rie Lopez, MPH (she/her) @RieOfLetters TIL: More about some of the latest #clinicaltrial options and I have a lot of resources to read through and share. Thank you! #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @GraceCordovano: TIL: TIL: PRO are not a nice to have, they are a must in clinical trial design. #gyncsm |
| ASCO @ASCO We're so glad we had the chance to join you all this evening! Please feel free to DM us or email tapur@asco.org w/ any f/u Qs #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm I want to thank each and every participant tonight for sharing your insights, questions and experiences. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin #gyncsm https://t.co/o1o6pJafYC |
| Dr. Lisa Aiello @aiellolisa136 @gyncsm TIL about PROs #gyncsm |
| Christina Lizaso @btrfly12 RT @RieOfLetters: TIL: TIL: More about some of the latest #clinicaltrial options and I have a lot of resources to read through and share. Thank you! #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @womenofteal: TIL Since DX the cliincal trial landscape has changed but there is still a need to improve access to more patients & rpt PROS. #gyncsm |
| Dee Sparacio @womenofteal @garmischgirl Do you know Georgia @shewithlynch she may be able to help find trials. #gyncsm |
| Dr. Lisa Aiello @aiellolisa136 @gyncsm This has been a great chat!! #gyncsm |
| Enlightening Results 💡 @GraceCordovano And to all a good night! Til next time #gyncsm https://t.co/OnAjvpyArY |
| Dee Sparacio @womenofteal Me too! RT @gyncsm: I want to thank each and every participant tonight for sharing your insights, questions and experiences. #gyncsm |
| Kathleen Maxian @KathleenMaxian RT @ShannonWestin: #gyncsm https://t.co/o1o6pJafYC |
| Dee Sparacio @womenofteal @GraceCordovano See you next month #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte Thanks so much for all the education and inspiration you provide, @womenofteal and @btrfly12!!! #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: We also greatly appreciate all clinical trial participants - past, present and future - for your amazing contributions to medicine #gyncsm |
| Erica Bednar @EMBOSU TIL clinical trials are a semi-foreign topic for most people (even some clinicians!). Lots of room for edu and improved access #gyncsm https://t.co/JWJqbGxSIC |
| Rie Lopez, MPH (she/her) @RieOfLetters @gyncsm Thank you! Excellent chat. Very informative and great to be with such a wonderful group. #gyncsm |
| Dee Sparacio @womenofteal Grateful for our #gyncsm co-moderators! @btrfly12 @ShannonWestin @DrMarkham @journeycancer @DrBeckerSchutte |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin Thanks to everyone for a great chat! See you next time!! #gyncsm |
| Janet Freeman-Daily @JFreemanDaily Thanks for a great topic! When more patients participate in #cancer clinical trials, many cancer patients will benefit. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Thanks so much for joining @JFreemanDaily - You are a wonderful research advocate. Thanks for all you do. #gyncsm |
| Dee Sparacio @womenofteal Remember to check https://t.co/Df2f7Okp35 for a transcript of the chat and resources #gyncsm |
| Georgia Hurst @shewithlynch RT @womenofteal: @garmischgirl Do you know Georgia @shewithlynch she may be able to help find trials. #gyncsm | |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin @womenofteal @btrfly12 @DrMarkham @journeycancer @DrBeckerSchutte Love working with you! #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Thanks to everyone for the wonderful conversation. Next #gyncsm chat: Wed, Nov 8th at 9pmET on Endometrial/Uterine Cancers. |
| Dee Sparacio @womenofteal @gyncsm @JFreemanDaily Thanks Janet for sharing your experience and expertise! #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @gyncsm: Thanks to everyone for the wonderful conversation. Next #gyncsm chat: Thanks to everyone for the wonderful conversation. Next #gyncsm chat: Wed, Nov 8th at 9pmET on Endometrial/Uterine Cancers. |
| GYN Cancer | #GYNCSM @gyncsm Remember to tweet things of interest with hashtag #gyncsm to keep the conversation going between chats. |
| Merry-Jennifer Markham, MD, FACP, FASCO @DrMarkham Thanks to you all. We've got a great group here. #gyncsm https://t.co/IUdLhuj7f5 |
| GYN Cancer | #GYNCSM @gyncsm Patients and caregivers are invited to continue our discussion on the Smart Patients platform at https://t.co/dFCf1Mcahw #gyncsm |
| Erica Bednar @EMBOSU Thank you @gyncsm for coordinating the great chat on clinical trials! Have a great evening, everyone! #gyncsm |
| Liz Cramer @oncELLEogy RT @SuzieSiegel: T1: T1: It's important for patients to understand that #clinicaltrials are NOT the treatment of last resort. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @gyncsm: Patients and caregivers are invited to continue our discussion on the Smart Patients platform at https://t.co/dFCf1Mcahw #gyncsm |
| Christina Lizaso @btrfly12 Resource | Understanding Clinical Trials - Your Guide https://t.co/uGsOAEelRT via @gyncancer #gyncsm |
| Liz Cramer @oncELLEogy RT @JFreemanDaily: T1b: Drawbacks of trials: T1b: Drawbacks of trials: hard to find "best" trial for you, may require travel & time away from family, varying level of risk #gyncsm |
| Dee Sparacio @womenofteal Thanks @btrfly12 for being my partner in all things #gyncsm . Couldn't do this without you. |
| Tobey @BRCAinfo RT @womenofteal: Grateful for our #gyncsm co-moderators! @btrfly12 @ShannonWestin @DrMarkham @journeycancer @DrBeckerSchutte |
| Jillosopher, BSN, RN @jillosopher @JFreemanDaily Thank you for explanations of trial types. So helpful. #gyncsm |
| Christina Lizaso @btrfly12 @womenofteal Such a wonderful partnership. Have a great rest of your week :) #gyncsm |
| Suzie Siegel @SuzieSiegel RT @JFreemanDaily: T5: T5: Consider having your #gyncsm tumor undergo broad genomic testing to help researchers identify targetable genomic drivers. |
| Jillosopher, BSN, RN @jillosopher RT @gyncsm: Thanks to everyone for the wonderful conversation. Next #gyncsm chat: Thanks to everyone for the wonderful conversation. Next #gyncsm chat: Wed, Nov 8th at 9pmET on Endometrial/Uterine Cancers. |
| Dee Sparacio @womenofteal Patients and caregivers are invited to continue our discussion on the Smart Patients platform at https://t.co/CwNPWNrWjY #gyncsm |
| Liz Cramer @oncELLEogy RT @JFreemanDaily: T2: T2: TAPUR is an option for patients to access targeted drug that is approved for a different cancer than theirs #gyncsm |
| Liz Cramer @oncELLEogy RT @ASCO: T3: T3: PROs are anything reported directly by the patient, like symptoms or emotions. They reflect how patients feel & function #gyncsm |
| Dee Sparacio @womenofteal @btrfly12 Thanks! #gyncsm |
| Jillosopher, BSN, RN @jillosopher @womenofteal @btrfly12 Thank you both! <3 #gyncsm |
| Liz Cramer @oncELLEogy RT @JFreemanDaily: T1: New trial design: T1: New trial design: "basket trial" offer single treatment for all cancers with specific biomarker (like ROS1 fusions) #gyncsm |
| Suzie Siegel @SuzieSiegel RT @ShannonWestin: T5: T5: Important to advocate for MORE research funding for the @NIH and @theNCI - more funds = more trials. Call your congressman! #gyncsm |
| Enlightening Results 💡 @GraceCordovano RT @womenofteal: Patients and caregivers are invited to continue our discussion on the Smart Patients platform at https://t.co/CwNPWNrWjY #gyncsm |
| Christina Lizaso @btrfly12 @jillosopher @womenofteal @btrfly12 you are more than welcome - reach out anytime :) #gyncsm |
| Dee Sparacio @womenofteal Till next month everyone >>> Wed, Nov 8th at 9pmET on Endometrial/Uterine Cancers. #gyncsm |
| Dee Sparacio @womenofteal @jillosopher @womenofteal @btrfly12 You're very welcome. #gyncsm |
| Liz Cramer @oncELLEogy Esp when considering cost of treatment if of label and a site is local. #gyncsm https://t.co/0AMIQ68rvm |
| Dee Sparacio @womenofteal RT @gyncsm: Thanks to everyone for the wonderful conversation. Next #gyncsm chat: Thanks to everyone for the wonderful conversation. Next #gyncsm chat: Wed, Nov 8th at 9pmET on Endometrial/Uterine Cancers. |
| Jillosopher, BSN, RN @jillosopher Goodnight #gyncsm See you around the twittersphere and again at next month's chat. |
| GYN Cancer | #GYNCSM @gyncsm Thanks again all! Look for the transcript shorty and the recap on the blog later. :) #gyncsm |
| Suzie Siegel @SuzieSiegel We need more #clinicaltrials for gyn #sarcoma! Read about the crisis in funding ... https://t.co/IyHqgLW5Ga |
| Liz Cramer @oncELLEogy RT @ShannonWestin: T1: T1: The MATCH trial run by @theNCI selects specific treatments based on the molecular abnormalities found in a patient's tumor #gyncsm |
| Liz Cramer @oncELLEogy RT @JFreemanDaily: T2: T2: For example, patient with ROS1+ cancer that started in colon can get ROS1 targeted drug approved for lung cancer #gyncsm |
| Liz Cramer @oncELLEogy RT @ShannonWestin: T1: T1: There are study designs called "basket trials" that include all #cancer types - these trials focus on specific molecular changes #gyncsm |
| Dee Sparacio @womenofteal A few more resources coming your way re :#clinicaltrials #gyncsm |
| Dee Sparacio @womenofteal Resources: @cancerdotnet Pre-ACT videos on clinical trials https://t.co/WVTz8nb60M #gyncsm |
| Dee Sparacio @womenofteal General resources : @cancerdotnet https://t.co/X9UglxxHBV #gyncsm |
| Dee Sparacio @womenofteal TAPUR https://t.co/P7rbXitGMf #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm @ShereesePubHlth always great to see you - thanks for joining #gyncsm |
| Dee Sparacio @womenofteal Patient Safety in Clinical Trials Video by @theNCI https://t.co/OnozzuKT2A #gyncsm |
| Dee Sparacio @womenofteal Physician and Patient Participation in Cancer Clinical Trials #gyncsm |
| Dee Sparacio @womenofteal https://t.co/0ToLAbJB8x #gyncsm |
| Dee Sparacio @womenofteal Patients’ willingness to participate in clinical trials https://t.co/LTM6PCOlTz #gyncsm |
| Suzie Siegel @SuzieSiegel RT @JFreemanDaily: T1b: Drawbacks of trials: T1b: Drawbacks of trials: hard to find "best" trial for you, may require travel & time away from family, varying level of risk #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm RT @womenofteal: Patients’ willingness to participate in clinical trials https://t.co/LTM6PCOlTz #gyncsm |
| Dee Sparacio @womenofteal Know ur risk for ovarian cancer, get genetic testing @ no cost. Enroll here: https://t.co/d9ZjsipHeP. #SU2CMAGENTA #gyncsm |
| Suzie Siegel @SuzieSiegel RT @womenofteal: T3 @theNCI article https://t.co/Q44Erv4LLP #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm RT @EMBOSU: T1: T1: clinical trials help move us beyond anecdotes & stories to real data to ensure best options to treat and #endcancer #gyncsm https://t.co/gJGk3r7g0E |
| Suzie Siegel @SuzieSiegel RT @womenofteal: T2 more info on TAPUR on @cancerdotnet https://t.co/s6tr25n2Nb #gyncsm |
| Suzie Siegel @SuzieSiegel RT @ASCO: T2: TAPUR is for pts >12yo w/ adv. cancer & at least 1 genomic alteration targetable by a study drug. More: T2: TAPUR is for pts >12yo w/ adv. cancer & at least 1 genomic alteration targetable by a study drug. More: https://t.co/1IQz9miZtg #gyncsm |
| Suzie Siegel @SuzieSiegel RT @ShannonWestin: T1: T1: The MATCH trial run by @theNCI selects specific treatments based on the molecular abnormalities found in a patient's tumor #gyncsm |
 | Spannerinmyworks @SpannerInMe RT @womenofteal: Know ur risk for ovarian cancer, get genetic testing @ no cost. Enroll here: https://t.co/d9ZjsipHeP. #SU2CMAGENTA #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm RT @ShannonWestin: @crazyknit68 @gyncsm @SGO_org The combined cooperative groups means that the money is divided by three - this means less trials per group #gyncsm |
 | Dr. Lisa Aiello @Lba34Lisa @BRCAinfo @garmischgirl Clinical Trial Nurses are key!#gyncsm |
| Dee Sparacio @womenofteal #gyncsm https://t.co/UXNX7kzE1I |
| Suzie Siegel @SuzieSiegel RT @ASCO: @womenofteal Absolutely! This is something we've been focusing on: @womenofteal Absolutely! This is something we've been focusing on: https://t.co/giQ94TMIO5 #gyncsm |
| Suzie Siegel @SuzieSiegel RT @ASCO: T1: Check out our guide for more info on new trial designs & precision medicine: T1: Check out our guide for more info on new trial designs & precision medicine: https://t.co/xqqrELXFy3 #gyncsm |
 | Taylor B. Rogers, PhD, MPH @taybrogers But why? 🤔 ... That is the question. #cervivor #cervicalcancer https://t.co/UPj6jLkJ5m |
| GYN Cancer | #GYNCSM @gyncsm RT @EMBOSU: TIL clinical trials are a semi-foreign topic for most people (even some clinicians!). Lots of room for edu and improved access #gyncsm https://t.co/JWJqbGxSIC |
| Suzie Siegel @SuzieSiegel RT @womenofteal: Patients’ willingness to participate in clinical trials https://t.co/LTM6PCOlTz #gyncsm |
| Dr. Lisa Aiello @Lba34Lisa RT @LguzzardiM: #Genetictesting helps identify #hereditarycancer syndromes #BRCA #VUS #GINA #HBOC #bcsm #gyncsm @masslivenews https://t.co/QC5fcf2n2L |
 | Marybeth Singer @marybeth_singer RT @ASCO: T3: T3: Research has shown that when patients self-report symptoms, they have better outcomes https://t.co/cjl8npOxVE #gyncsm |
#GynCSM content from Twitter.